Ownership and insider activity for ICON Public Limited Company (ICLR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Price
| Price | $211.36 (closing price, October 30, 2026) |
| Market Cap | $16.3B |
| Exchange | NASDAQ |
| Country | IE |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-22 | Lyons Emer | M-Exempt | 510 | |
| 2026-10-23 | Lyons Emer | S-Sale | 42 | $8K |
| 2026-10-23 | Lyons Emer | S-Sale | 81 | $15K |
| 2026-10-23 | Lyons Emer | S-Sale | 43 | $8K |
| 2026-10-23 | Lyons Emer | S-Sale | 52 | $10K |
| 2026-10-23 | Lyons Emer | S-Sale | 54 | $10K |
| 2026-10-22 | Lyons Emer | M-Exempt | 510 | |
| 2026-09-16 | CLIMAX JOHN DR | M-Exempt | 5,005 | $629K |
| 2026-09-16 | CLIMAX JOHN DR | S-Sale | 5,005 | $876K |
| 2026-09-16 | CLIMAX JOHN DR | M-Exempt | 5,005 | $629K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192.5M | $282.9M | $395.9M | $520.3M | $840.3M | $752.2M | $288.8M | $378.1M | $538.8M | $647.3M |
| Short-term Investments | $68.0M | $77.6M | $59.9M | $49.6M | $1.7M | $1.7M | $1.7M | $2.0M | 0 | 0 |
| Receivables | $662.2M | $706.2M | $837.6M | $1.01B | $1.21B | $2.07B | $2.80B | $2.90B | $2.85B | $2.75B |
| Inventory | $2.4M | $2.2M | $2.3M | $3.2M | 0 | 0 | $7.1M | 0 | 0 | 0 |
| Total Current Assets | $958.0M | $1.10B | $1.33B | $1.62B | $2.10B | $2.94B | $3.23B | $3.41B | $3.53B | $3.50B |
| Property, Plant & Equipment | $149.0M | $105.1M | $103.7M | $270.1M | $258.9M | $534.6M | $504.2M | $501.5M | $530.5M | $524.7M |
| Goodwill | $616.1M | $783.1M | $770.3M | $883.2M | $936.3M | $9.04B | $8.97B | $9.02B | $9.05B | $8.73B |
| Intangible Assets | $56.6M | $129.6M | $109.0M | $67.9M | $66.5M | $4.71B | $4.28B | $3.86B | $3.56B | $3.25B |
| Total Assets | $1.83B | $2.19B | $2.35B | $2.91B | $3.44B | $17.39B | $17.19B | $16.99B | $16.88B | $16.27B |
| Accounts Payable | $8.7M | $18.6M | $13.3M | $24.1M | $51.1M | $227.0M | $611.4M | $595.5M | $704.6M | $780.9M |
| Short-term Debt | 0 | 0 | 0 | $349.6M | 0 | $55.1M | $55.1M | $110.2M | $29.8M | $529.8M |
| Total Current Liabilities | $494.4M | $566.1M | $610.6M | $1.13B | $1.12B | $2.48B | $2.69B | $2.83B | $2.80B | $3.20B |
| Long-term Debt | $348.5M | $348.9M | $349.3M | 0 | $348.5M | $5.38B | $4.60B | $3.67B | $3.40B | $2.87B |
| Total Liabilities | $880.7M | $955.6M | $1,000.0M | $1.29B | $1.59B | $9.32B | $8.69B | $7.75B | $7.35B | $7.08B |
| Retained Earnings | $587.8M | $742.8M | $888.3M | $1.11B | $1.26B | $1.42B | $1.82B | $2.43B | $2.72B | $2.12B |
| Total Equity | $945.2M | $1.19B | $1.35B | $1.62B | $1.85B | $8.07B | $8.50B | $9.24B | $9.52B | $9.19B |
| Total Debt | $348.5M | $348.9M | $349.3M | $454.6M | $433.6M | $5.65B | $4.83B | $3.94B | $3.60B | $3.56B |
| Net Debt | $87.9M | -$11.6M | -$106.5M | -$115.4M | -$408.4M | $4.89B | $4.54B | $3.56B | $3.06B | $2.91B |
| Working Capital | $463.6M | $535.0M | $719.6M | $493.7M | $979.0M | $462.3M | $538.5M | $585.9M | $734.1M | $305.5M |
Financial Health
| Debt / Equity | 0.38 |
| Current Ratio | 1.32 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 2.13 |
Profitability
| Return on Equity | 4.85% |
| Return on Invested Capital | 4.85% |
| Return on Assets | 2.76% |
| Gross Margin | 21.19% |
| Operating Margin | 9.46% |
| Net Margin | 5.45% |
Related companies: MEDP · FTRE · IQV · LH · CRL
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of ICLR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks